TerminatedNot Applicable

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Stopped: Accrual goal met

United States210 participantsStarted 2018-09-21

Plain-language summary

This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center in order to conduct correlative studies of the immune system, microbiota, and their interactions. Fluid (including but not limited to, blood, urine, saliva, cerebrospinal fluid, bronchoalveolar lavage fluid) sample log-in, processing, relabeling, and storage is performed by the Masonic Cancer Center (MCC) Translational Therapy Lab (TTL).

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients planning to undergo HCT or other cellular therapy/immunotherapy * Allogeneic related donors * Aged 0-80 * Willing and able to sign voluntary written consent Exclusion Criteria: * Patients whose medical record indicates that they have opted out of research

What they're measuring

Immune Function after HCT

Timeframe: 7 Years

Immune Function after HCT

Timeframe: 7 Years

Immune Function after HCT

Timeframe: 7 Years

Immune Function after HCT

Timeframe: 7 Years

Immune Function after Cell Therapy/Immunotherapy

Timeframe: 7 Years

Immune Function after Cell Therapy/Immunotherapy

Timeframe: 7 Years

Immune Function after Cell Therapy/Immunotherapy

Timeframe: 7 Years

Correlate Immune Parameters

Timeframe: 7 Years

Correlate microbiota changes and their interactions with the host with outcomes of HCT

Trial details

NCT IDNCT03557749

SponsorMasonic Cancer Center, University of Minnesota

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-30

View on ClinicalTrials.gov More Immune and Microbial Reconstitution trials